Acura and King Pharmaceuticals, which Pfizer recently purchased, tried to gain FDA approval for Acurox back in 2009. The medication combines Purdue Pharmaceuticals' OxyContin with an abuse-resistant technology from Acura that makes it hard for drug abusers to extract the active ingredient, oxycodone.
At the time, the duo was also adding niacin to the drug to deter abuse. Niacin is the active ingredient in Abbott Labs'
But the drama only continued. When the companies resubmitted last year, the FDA said it wanted more information about the ability of addicts to snort the drug. We won't know for certain whether the companies have satisfied the agency until it hands down its ruling.
There's clearly a need for these abuse-resistant pain drugs, but it's been a drawn-out process proving to the FDA that they really do what they're supposed to. King, Pain Therapeutics
What do you think are the chances that Acurox gains an FDA approval tomorrow? Take our Foolish poll and fill in the details in the comments box below.
Fool contributor Brian Orelli holds no position in any company mentioned. See his holdings and a short bio. The Motley Fool owns shares of Abbott Laboratories. Motley Fool newsletter services have recommended buying shares of Pfizer and Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Stocks That Are Cash Cows
It's not just the cash. It's what these companies do with it that really matters.
Why 2017 Was a Year to Forget for Pfizer Inc.
Pfizer's 2017 wasn't horrible. Just ho-hum.
3 Dividend Stocks to Buy on Sale
It's hard to go wrong with high dividend yields, low earnings multiples, and solid long-term business prospects.